bevacizumab biosimilar
/ Axis Biotec, Fraunhofer-Institute of Toxicology and Experimental Medicine, PlantForm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 13, 2022
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
(PubMed, Cells)
- "The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response."
Biomarker • Journal • Gastrointestinal Cancer • Hepatoblastoma • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • MIR122 • MIR193B • MIR194 • MIR200C • MIR222 • MIR27A • MIR375
May 26, 2017
Bevacizumab biosimilar: Launch in world markets in between 2022-2024
(PlantForm Corporation)
- Investor Presentation
Biosimilar launch • Biosimilar
1 to 2
Of
2
Go to page
1